WEKO3
アイテム
Efficacy and feasibility of dose-dense neoadjuvant chemotherapy versus conventional neoadjuvant chemotherapy in patients with HER2-negative breast cancer: A single-center retrospective study
http://hdl.handle.net/10069/00042154
http://hdl.handle.net/10069/0004215434b4c182-0635-4a05-b8ff-8ea9767b6269
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ActMed66_51.pdf (559.7 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2023-03-30 | |||||
| タイトル | ||||||
| タイトル | Efficacy and feasibility of dose-dense neoadjuvant chemotherapy versus conventional neoadjuvant chemotherapy in patients with HER2-negative breast cancer: A single-center retrospective study | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Dose-dense chemotherapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Breast cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Neoadjuvant | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Feasibility | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 著者 |
Minami, Shigeki
× Minami, Shigeki× Sakimura, Chika× Akashi, Momoko× Yukutake, Aki× Irie, Junji |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: Dose-dense chemotherapy (DDCT) is a standard treatment for patients with high-risk breast cancer. Although there are numerous reports regarding DDCT, it is unclear whether sequential DDCT is effective or feasible as preoperative treatment for Japanese patients. We evaluated the efficacy and safety of neoadjuvant DDCT for patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: This retrospective study evaluated 39 patients with breast cancer, who were preoperatively treated with anthracyclinecontaining regimens and taxanes. According to the chemotherapy regimens patients were divided into the DDCT group (ddgroup) and the conventional chemotherapy (CCT) group (q3w-group). The efficacy of neoadjuvant chemotherapy was evaluated based on the pathological complete response (pCR) rate. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Results: There were no apparent differences in tumor stage, histopathological subtype, or surgical procedure. There was not significant difference in the pCR rate (dd-group, 17.6%; q3w-group, 22.7%). Three-year disease-free survival rates were similar in two groups. The rates of dose reduction, delay of treatment, and discontinuation of treatment in the two groups did not differ to a statistically significant extent. There were no significant differences in the adverse events of the two groups. |
|||||
| 書誌情報 |
Acta medica Nagasakiensia 巻 66, 号 2, p. 51-56, 発行日 2023-03 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00016055 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00508430 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 出版者 | ||||||
| 出版者 | Nagasaki University School of Medicine | |||||
| 出版者別言語 | ||||||
| 値 | 長崎大学医学部 | |||||
| sortkey | ||||||
| 値 | 02 | |||||
| 引用 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Acta medica Nagasakiensia, 66(2), pp.51-56; 2023 | |||||
